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Edited by Robert BaroukiAbstract The study of molecular chaperones (genetics, struc-
ture, location, physiology, pathology, and therapeutics) has
developed into a science with speciﬁc objectives, methods, and
hypotheses, a discipline we called chaperonology. Subdisciplines
of chaperonology include the study of pathological chaperones
(chaperonopathies) and the analysis of their genes in sequenced
genomes (chaperonomics). Chaperonopathies are pathological
conditions in which one type of chaperone is deﬁcient due to a ge-
netic or acquired defect that modiﬁes the chaperone’s structure
and/or makes the chaperone unavailable for functioning when
needed. Experimental and clinical data show that chaperones
and their genes can be used for treating various pathological con-
ditions, thus justifying the development of chaperonotherapy. We
discuss recent work showing that chaperonotherapy is on solid
foundations: the data demonstrate that molecular chaperones
counteract pathogenetic mechanisms in disease and during stress.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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aggregation1. Introduction
The main objective of this minireview is to provide a brief
account of a new ﬁeld of science, medicine in particular, which
is emerging as a result of many years of basic research on
stress, stress proteins, and molecular chaperones. Stress is an
everpresent factor in the life of all organisms and these possess
a variety of antistress mechanisms to counteract those eﬀects
of stress that may be deleterious if left unchecked. For it is pos-
sible that not all consequences of stress are deleterious butAbbreviations: Hsp, heat-shock protein; TUNEL assay, deoxynucleo-
tidyl transferase-mediated deoxyuridine triphosphate nick end labeling
assay; SOD1, superoxide dismutase 1; FALS, familial amyotrophic
lateral sclerosis; SDS, sodium-dodecylsulfate; BAG1, Bcl-2-associated
athanogene 1, where Bcl stands for B-cell leukemia/lymphoma 2; APP,
amyloid precursor protein; ER, endoplasmic reticulum; PPIase,
peptidyl-prolyl cis–trans isomerase; AS, a-Synuclein; UPS, ubiquitin–
proteasome system; DRM, desmin-related myopathy; SBMA, spinal
and bulbar muscular atrophy; AR, androgen receptor; GGA, gera-
nylgeranylacetone; siRNA, small inhibitory RNA
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doi:10.1016/j.febslet.2007.04.030some could be stimulatory, as if stress were a challenge for
developing certain cellular and organismal properties and for
keeping them functional throughout life.
This minireview will focus on molecular chaperones, some of
which but not all are a subset of stress proteins. Among the
stress proteins, those that are produced upon induction of their
parent genes by heat shock are called heat-shock proteins
(Hsp), a term that for historical reasons and because of wide-
spread usage is often considered a synonym of molecular chap-
erone, although this does not always apply since some
chaperones are the product of genes that are not inducible
by heat shock. Perhaps the property common to all chaperones
is that they assist other proteins in various ways, chieﬂy in con-
nection with acquiring and maintaining their native, functional
conformation, and thus chaperones are essential for maintain-
ing protein homeostasis, including degradation of defective
proteins and peptides. By extension, some have included under
the chaperone name proteins that assist non-protein molecules,
e.g., RNA, in their assembling to build a functional structure,
and also, one has to remember that there are many compounds
that are not proteins but can assist proteins in folding and
refolding as the typical molecular chaperones do.
The study of Hsps, the canonical molecular chaperones, and
other molecules, proteins or not, that assist other molecules in
acquiring and maintaining a functional shape, and thus in
assuring that there is always a full set of proteins in their prop-
er conformation at the concentrations required in each cell
compartment and tissue, has progressed immensely in the last
30 years, and as a result a huge amount of information has
accumulated. This information is disperse, and mostly uncon-
nected, a situation that calls for eﬀorts to delineate a ﬁeld that
would encompass pertinent data, methods, and ideas, in a sys-
tematic manner, so as to facilitate analysis by experts and
study by newcomers to this ﬁeld, including the general public.
We call this ﬁeld chaperonology.2. Chaperonology and its main disciplines
Antistress mechanisms in general, beyond chaperones, have
been studied for a very long time and many factors have been
identiﬁed that participate in these mechanisms, factors that re-
side intracellularly and outside cells, i.e., the cell’s surface and
the extracellular space, including the intercellular connective
material in multicellular tissues and organisms. It stands to
reason that if there are factors (e.g., proteins) that participate
in antistress mechanisms there have to be instances in which
one or more of these factors are abnormal due to mutationblished by Elsevier B.V. All rights reserved.
Fig. 2. Major events in the ageing of proteins and molecular
chaperones that reﬂect the decline of many biological processes during
senescence and, in turn contribute to this decline. Also shown is the
central role of normal chaperones when available to prevent and
counteract the consequences of protein damage. This latter fact is at
the basis of chaperonotherapy, in which chaperone replacement would
be the indicated strategy.
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abnormality may have an impact on the antistress mechanism
in which the aﬀected factor participates and thus cause a path-
ological condition, or at least facilitate the development of
such a pathological condition if a primary etiologic agent
comes into the scene and takes advantage of the antistress
mechanism deﬁciency. The pathology of antistress mechanisms
was presented as a possibility sometime ago with emphasis on
the role that defective chaperones might play [1–3]. It was pro-
posed that if the deﬁcient factor is a chaperone, then the con-
dition might be called a chaperonopathy. This minireview
focuses on chaperonopathies, which were recently classiﬁed
as genetic or acquired [4,5].
Various subﬁelds are identiﬁable within chaperonology.
Thus far we have dealt with chaperonopathies and their classi-
ﬁcation (references above), and with their analysis at the level
of genes and genomes, a discipline we called chaperonomics
[6]. Here, we will discuss chaperonotherapy, namely the use
of chaperones for prevention and treatment of pathological
conditions that might beneﬁt from the use of chaperones as
therapeutic agents. The use of chaperones for treatment of var-
ious pathological conditions, particularly cancer, has been ex-
plored for several years and the practical aspects of the topic
have been reviewed elsewhere by others (see below). Here,
we will provide the basis for chaperonotherapy chieﬂy as it
pertains to the treatment of chaperonopathies.3. Types of chaperonopathies
Chaperones can participate in pathogenesis in various ways,
but in this minireview we will concentrate almost exclusively
on conditions in which the chaperone itself is deﬁcient, because
of a structural defect genetic or acquired, or because the chap-
erone although structurally normal is unable to function, as it
would be the case of sequestration of a normal chaperone in a
protein deposit. Fig. 1 presents schematically the pathologic
scenario due to a genetic defect of a chaperone with impact
on function and thus on the normal functioning of a cell.
The ensuing chaperonopathy will most likely be hereditary,
clinically complex with many tissues and organs aﬀected dueFig. 1. Main features of genetic chaperonopathies. Also shown is the
central role that normal chaperones, if made available, would play as
therapeutic agents. The genetic chaperonopathies are indeed appro-
priate candidates for chaperonotherapy in the form of chaperone
replacement.to the various roles of chaperones in many anatomic locations,
and possibly of early onset. Normal chaperones if therapeuti-
cally provided are likely to correct the eﬀects due to the deﬁ-
cient chaperone, and thus the pathological condition might
be considered a candidate for chaperonotherapy.
A situation due to an acquired protein defect such as that
occurring in ageing, compounded by a similar defect of chap-
erones, which like other proteins are susceptible to damage
during senescence, is outlined in Fig. 2. Progressive protein
damage due to oxidation and other aberrant posttranslational
modiﬁcations expands the pool of proteins requiring assistance
from chaperones. However, chaperones also very probably be-
come damaged during senescence and thus become progres-
sively less eﬃcient. The predicted outcome is a progressive
perturbation of protein homeostasis that could very well be
one of the major factors in the generation of the general func-
tional decline characteristic of ageing.
The situation just described could be complicated further by
stressors that are likely to be present during life but even moreFig. 3. Series of events characterizing various pathologic states of
increasing severity due to the participation of several pathogenetic
factors, stress, protein defects (congenital and/or acquired), and
chaperone deﬁciency. Normal chaperones if made available would
have a beneﬁcial impact in as much as they would contribute to the
folding and refolding of damaged proteins, to the dissolution of
protein aggregates before they become irreversible precipitates, and to
the elimination of peptides beyond repair, and thus chaperonotherapy
would also decrease the formation of protein deposits.
A.J.L. Macario, E. Conway de Macario / FEBS Letters 581 (2007) 3681–3688 3683so in the elderly. The whole picture is outlined in Fig. 3, in
which are shown the various possible pathogenetic factors such
as protein damage and chaperone deﬁciency, which lead to
protein aggregation and precipitation with formation of irre-
versible protein deposits and cell pathology or even cell death.
Once again, it is evident that the need for normal ‘‘young’’
chaperones could be satisﬁed via chaperonotherapy.4. Chaperonotherapy
The therapeutic use of chaperones has been investigated for
many years and the clinical indications, strategies, problems,
and results have been extensively reviewed [1,7–9]. We will
not attempt in this article to provide another comprehensive
review on this topic but we will rather present the basis for
chaperonotherapy chieﬂy as it pertains to chaperonopathies,
and we will give selected examples of the various possible strat-
egies for implementing this type of treatment.5. Parallelism between increase in chaperone levels and
cytoprotection against stressors and prevention of protein
aggregation
A number of reports show that cell resistance to stressors is
improved when the levels of molecular chaperones are higher
and that resistance is diminished if chaperone levels are lower
than the normal ones. This, expressed in a manner pertinent to
the assessment of the justiﬁcation for developing chaperono-
therapy as a viable therapeutic strategy, means that by increas-
ing chaperone levels one can expect improved cytoprotection
and survival. A small sample of recent articles reporting asso-
ciation between chaperone levels and stress resistance are dis-
cussed below.
The levels of Hsc70 were investigated in brain cells from rats
that had been exposed to whole body hyperthermia [10]. Un-
der these conditions of hyperthermia, many brain cells die. Cell
death was measured using the terminal deoxynucleotidyl trans-
ferase-mediated deoxyuridine triphosphate nick end labeling
(TUNEL) assay. Cell death was assessed by immunohisto-
chemistry. Hyperthermia induced elevated levels of Hsc70 in
neurons of the dentate gyrus, and CA1 and CA2 regions of
the hippocampus, and in Purkinje neurons in the cerebellum,
which coincided with absence of cell death in all these regions.
The same association pattern was observed in the thymus and
testis: in regions with cells containing elevated levels of the
chaperone no cell death was recorded.
Similarly, another article reports that overexpression of
Hsp70 reduced accumulation of a mutant protein with ten-
dency to aggregate and precipitate [11]. Misfolded Cu/Zn
superoxide dismutase 1 (SOD1) accumulates in patients with
familial amyotrophic lateral sclerosis (FALS). Experimentally,
mice expressing mutant SOD1 showed aggregates of this pro-
tein. The levels of sodium-dodecylsulfate (SDS)-dissociable
aggregates and SDS-stable dimers were found elevated before
motor dysfunction began to appear. Overexpression of Hsp70
reduced accumulation of mutant, insoluble SOD1. This is
important because, in FALS, SOD1 increases with disease pro-
gression, forming aggregates and precipitates. These pathoge-
netic manifestations are even more marked if the proteasomeand/or the chaperoning systems fail: inhibition of the protea-
some and/or chaperone activity favored accumulation of
SOD1 and disease aggravation.
Bcl-2-associated athanogene 1, where Bcl stands for B-cell
leukemia/lymphoma 2 (BAG1) interacts with Hsp70, and is
neuroprotectant via its stimulation of this chaperone’s activity.
Rat and human cells overexpressing either normal BAG1 or a
mutant incapable of binding-interacting with Hsp70, showed
increased or decreased chaperoning activity by Hsp70, respec-
tively [12]. Moreover, cells overexpressing mutant BAG1 were
not protected from cell death caused by various apoptosis-
inducing agents. BAG1 binds via its BAG domain, located
near its C-terminus, the Hsp70 and Hsc70 N-terminal ATPase
domain and, thus, serves as a co-chaperone for productive
polypeptide folding, which leads to protein maturation and
to a ﬁnal, functional, native conformation. Defective BAG1
does not interact with Hsp70 and neuroprotection is abolished.
Another chaperone that has been found to prevent the
aggregation of unfolded polypeptides is the small heat-shock
protein (sHsp), Hsp27. For example, human Hsp27 (also de-
noted HSP27) overexpressed in Escherichia coli provided this
bacterium with an increased tolerance to heat shock [13].
Accumulation of amyloid beta peptides (A-beta), which are
produced by proteolysis of the b-amyloid precursor protein
(APP) is central to the pathogenesis of Alzheimer’s disease.
Consequently, numerous studies have been focused on under-
standing how the peptides are generated and how their produc-
tion and aggregation can be prevented. One approach to the
latter prevention of aggregation involves chaperones, which
are known to interfere with pathologic aggregation of abnor-
mal proteins. In one study, the eﬀect of overexpression of
ER-residing chaperones on the generation of A-beta peptides
from a mutant APP (APPsw) was examined in cultured cells
[14]. When Grp78 was overexpressed, the levels of A-beta40
and A-beta42 decreased and the opposite result was observed
when the chaperone was kept below its basal levels. The
Grp78 eﬀect on decreasing peptide production was enhanced
by co-expressing its cochaperones, ERdj3 or ERdj4. Similarly,
overexpression of the 150 kDa oxygen regulated protein
(ORP150) and calnexin, both considered ER-residing chaper-
ones, also decreased A-beta production. In contrast, overex-
pression of another two ER-residing chaperones, Grp94 and
calreticulin, did not show an eﬀect on the levels of peptide
formed.
All the above reports indicate that molecular chaperones
(e.g., Hsp70, Hsp90, Hsp27, as well as some of their co-chap-
erones like BAG1, and some of the ER-residing chaperones)
protect against stressors by favoring correct protein folding
and by preventing aggregation of unfolded and misfolded
polypeptides generated because of stress or because of genetic
abnormalities, or both.6. Direct demonstration at the molecular level of the chaperoning
eﬀect in misfolding-protein pathology
6.1. Alzheimer’s disease
Pin1 is a chaperone, a peptidyl-prolyl cis–trans isomerase
(PPIase), that catalyzes cis–trans isomerization of Ser/Thr-
Pro motifs. This isomerization, which has an impact on the
functionality of proteins bearing the motif, occurs very slowly
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ics most likely has functional-pathological consequences. For
example, a lack of rapid isomerization of amyloid precursor
protein (APP) may favor generation of the toxic A-b peptide,
which is amyloidogenic [15]. In Alzheimer’s disease, a patho-
genic pathway would include overproduction and/or decreased
clearance of A-b peptide leading to formation of amyloid ﬁ-
bers, which aggregate and precipitate generating the extracellu-
lar plaques, typical of the disease. It was observed that Pin1
binds phosphorylated APP via its WW domain. This domain,
known to bind the Ser/Thr-Pro motif, was found to bind
Thr-668-Pro in APP, which lead to a non-amyloidogenic
APP processing (like the one promoted by alpha secretases
and in contrast to the amyloidogenic beta and gamma secreta-
ses). In this way, Pin1 reduces A-beta peptide production.
But when Pin1 was missing (e.g., gene knockout) A-beta
production increased. It was inferred that the cis Thr-668-
Pro conformation would be amyloidogenic, whereas the trans
conformation would lead to non-amyloidogenic APP process-
ing. By extrapolation, it was suggested that defects in Pin1 due
to mutation or post-translational modiﬁcations, including
those caused by oxidation, would favor progression of the Alz-
heimer’s pathology by allowing accumulation of APP in the cis
conformation. This work went a long way toward a direct
demonstration of the interaction of a chaperone’s deﬁned mo-
tif with a deﬁned motif on the substrate, and the conforma-
tional consequences of this interaction. It also showed the
harmful consequences of lack of proper interaction when the
chaperone is absent, and suggested that the same deleterious
eﬀects can occur when the chaperone is defective (e.g., ac-
quired or genetic Pin1 chaperonopathy).
In a similar work, the eﬀects of the chaperones Hsp70 and
Hsp90 on amyloid Beta-(1–42) aggregation were studied [16].
As mentioned above, a landmark of Alzheimer’s disease is
the presence of extracellular amyloid plaques in the brain.
These plaques are formed by amyloid ﬁbrils composed of
A-beta 2, which is a proteolytic fragment of 39–43 amino acids
derived from APP. The fragment becomes rich in beta sheets
and tends to self aggregate, forming oligomers that most prob-
ably are pathogenic. This implies that preventing the forma-
tion of oligomers will have beneﬁcial eﬀects, and this
possibility was explored in the work discussed here. It was re-
ported that Hsp70/Hsp40 and Hsp90 did prevent A-beta self
aggregation in vitro. The anti-aggregation activity of Hsp70
could be inhibited by a non-hydrolyzable nucleotide (substitut-
ing for ATP, the hydrolysis of which is necessary for Hsp70 to
exercise its chaperoning functions), and could be enhanced by
adding compounds with the capacity of stimulating the ATP-
ase activity of the chaperone (activity also required for the
chaperone’s work). Same treatment with the chaperones of
pre-formed oligomers and ﬁbrils had some eﬀect on the former
but none on the ﬁbrils, i.e., oligomers could be disaggregated
somewhat but the ﬁbrils remained unchanged in the presence
of the chaperones. The results indicate that if the chaperones
are present in the same cellular compartment in which the
A-beta fragments are produced, when the latter are being gen-
erated, aggregation of the fragments will be prevented, but
after they have aggregated they will be more resistant to disag-
gregation. Fibrils are even more stable, not susceptible to chap-
erone action. Thus, the work reported shows quite clearly that
chaperones play a direct role in preventing ﬁbril formation by
inhibiting the early stages of A-beta fragments self assembly.In conclusion, the data from the two articles discussed above
are very encouraging for chaperonotherapy in as much as they
show that molecular chaperones can prevent protein aggrega-
tion and deposition, and this eﬀect occurs via direct interaction
with defective peptides with tendency to self-assembly and pre-
cipitation, a pathological feature common to many important
diseases.6.2. Parkinson’s disease
A characteristic feature of protein misfolding pathologies,
among which are neurodegenerative diseases such as Parkin-
son’s, Alzheimer’s and Huntington’s, is the presence in brain
tissue of intra- and extracellular accumulation of protein olig-
omers, amorphous aggregates, ﬁbrils, and plaques. For exam-
ple, characteristic of Parkinson’s disease (PD) are the Lewy
bodies, which reside in the cytoplasm of dopamine neuron of
the midbrain, formed by alpha-Synuclein (AS) and other pro-
teins. AS is abundant in normal presynaptic terminals. Three
AS gene mutations, A53T, A30P, and E46K, have been impli-
cated in the pathogenesis of certain forms of familial PD. It
has also been shown that by increasing AS-gene expression
(e.g., in transgenic mice and fruit-ﬂies, and in animals with
cells transfected with viral vectors carrying the AS gene), a
pathology very similar to that observed in PD develops char-
acterized by neuronal dysfunction and loss, and protein depos-
its. AS and the mutants A53T and A30P were found to form
ﬁbril precursors, i.e., preﬁbrillar AS (PreAS), and ﬁbrils
in vitro. The presence of the ﬁbrils causes permeabilization
of membranes, and inhibition of the ubiquitin–proteasome sys-
tem (UPS). These basic lesions could be at the basis of the re-
ported ﬁbrils’ cytotoxicity. A recent article describes inhibition
of PreAS and ﬁbril formation by Hsp70 [17]. AS stays under
physiological conditions as an unfolded, soluble, monomeric
form, but stressors such as heat shock and decrease in pH
make it fold partially, which likely exposes hydrophic sites
and confers the protein a tendency to aggregate yielding PreAS
(a beta sheet-rich oligomer) with membrane permeabilization
ability. This ability does not seem to be shared with full ﬁbrils,
which however show another potentially cytotoxic capacity:
inhibition of UPS. The mechanism involved in the inhibition
of PreAS formation and ﬁbril elongation by Hsp70 includes
binding of Hsp70 to PreAS that reduces formation of initiation
nuclei, and binding to the fewer nuclei formed in the presence
of the chaperone, which slows down ﬁbril elongation. Interest-
ingly, only the Hsp70 substrate-binding domain is necessary
for inhibition of AS ﬁbril formation. However, while only
the substrate-binding domain (without the lid) can eﬀectively
bind PreAS, the lid is required to bind the nuclei.6.3. Huntington’s disease
The various known neuron types show unequal response to
the presence of mutant huntingtin. To investigate the reasons
for this variation in vulnerability among neurons and identify
possible protectors in those cells less aﬀected by the presence of
polyglutamine (polyQ) proteins, gene expression proﬁles were
examined. Hsp70 was found increased only in cells containing
mutant huntingtin, most noteworthy in cerebellar granule cells
[18]. Granule cells are known to be resistant to degeneration in
Huntington’s disease. However, when expression of Hsp70 was
suppressed with small inhibitory RNA (siRNA) in granule
cells, these cells underwent degeneration. In contrast, cortical
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presence of mutant huntingtin when Hsp70 was overexpressed
in them. In conclusion, Hsp70 appeared to protect neuron
from the degenerative eﬀects caused by abnormal polyQ pro-
teins.
6.4. Desmin related myopathy
Along the same lines discussed in the preceding paragraphs,
a recent article reports the use of sHsp22 and sHsp25 to pre-
vent oligomer formation by mutant alpha-B-crystallin
(CryAB), also a sHsp [19]. The mutant CryAB R120G has
been implicated in the causation of desmin-related myopathy
(DRM), a genetic conditions characterized by cardiomyopathy
and a number of other abnormalities. The pathogenic mutant
tends to aggregate and form protein deposits (aggregates).
These deposits contain desmin and amyloid oligomers and ﬁ-
brils made of the mutant sHsp. The role of protein deposits
in neurodegenerative diseases has not yet been clariﬁed: they
are considered beneﬁcial for the patient, neutral, or detrimen-
tal, depending on the author, and on the type of lesion and dis-
ease under consideration. For example, for some, the harmful
elements are not the insoluble amyloid ﬁbrils or the precipi-
tates but the soluble amyloid oligomers. A antibody is avail-
able that recognizes rather speciﬁcally soluble amyloid
oligomers, no matter their origin, i.e., A-beta(1–42) peptide
in Alzheimer’s disease, synuclein in Parkinson’s disease, poly-
glutamine protein in Huntington’s disease, or prion protein in
scrapie. This cross-reactivity suggests that oligomers of diﬀer-
ent origins all share a common antigenic structure, which al-
lows the use of the antibody as an identifying reagent for use
in various qualitative and semiquantitative assays. Some
experimental data indicate that soluble oligomers of CryAB
are required for pathogenesis in DRM. Therefore, the authors
attempted to inhibit oligomer formation by using other sHsp,
such as human Hsp22 and 25, administered to cultured cells
via transfection with an adenovirus vector. Indeed, oligomer
assembly was reduced as well as cell pathology. Interestingly,
the wild type CryAB formed much larger oligomers, and thus
much less toxic, than the mutant CryAB R120C (responsible
for DRM), which formed smaller but very toxic oligomers.
One may infer from these results that sHsp have therapeuti-
cal potential in those pathologies in which amyloid oligomers
are toxic since they seem to inhibit formation of the toxic olig-
omers.7. Molecular chaperone genes delivered into host cells with
various kinds of vectors
Molecular chaperone genes have been provided to cells in
viral vectors in various systems to test the protective eﬀect of
chaperones against the consequences of stress caused by di-
verse stressors, e.g. chemicals, radiation, and ischemia [20–
27]. Two recent examples of such attempts are discussed below.
The protective eﬀect of chaperones on the consequences of
stroke due to arterial occlusion was tested in rats [24]. hsp27,
and hsp70 genes were tested separately by administering one
or the other in an attenuated herpes simplex vector via micro-
injection into the stratium three days before ischemia induc-
tion. The volume of the lesion at 24 h after induction was
reduced signiﬁcantly in hsp27-treated animals in contrast to
hsp70-treated counterparts and controls microinjected withvirus carrying LacZ instead of a chaperone gene. The quanti-
ties of Hsp27 and Hsp70 proteins were similar in the respective
animals, but only Hsp27 reduced the lesion volume.
Similarly, it was demonstrated earlier, also in rats, that hsp27
did increase neuronal survival after administration of kainic-
acid, which is known to induce cell death [21]. Thus, the use
of certain chaperone genes delivered to neurons via an attenu-
ated neurotropic virus has potential for stroke management,
particularly to reduce lesion size and cell death.8. Administration of molecular chaperone proteins
Cell death caused by axotomy of the sciatic nerve was de-
creased by administration of Hsp70 proteins in neonatal mice
[23]. Exogenous preparations of Hsc70 and Hsp70 were tested,
along with measurements of the levels of the endogenous coun-
terparts before and after stress (axotomy) in lumbar motor
neurons and dorsal root ganglions sensory neurons. The basal
levels, i.e., constitutive levels, of endogenous proteins did not
increase after axotomy, indicating that this stressor does not
induce a stress response in the genes encoding these two pro-
teins in neonatal mice. Nonetheless, several diﬀerent prepara-
tions of exogenous Hsc70 and Hsp70 did reduce cell death.
The results suggested that neonatal mouse sensory and motor
neurons are unable to mount a stress response to traumatic in-
jury, and that this deﬁciency can be corrected by administering
exogenous chaperones.9. Chaperone cytoprotection seemingly independent of typical
polypeptide chaperoning activity
The use of mutant chaperones lacking a functional domain
[28] allows determination of which function is required, and
which is dispensable to achieve cytoprotection. In a recent
work it was shown that Hsp70 was eﬃcient to protect against
ischemic stress [29]. Mouse astrocytes were transfected with
plasmids carrying human wild type Hsp70, or a point mutant
ATPase deﬁcient, or a deletion mutant lacking the ATPase do-
main. All three proteins used, wild type and the two mutants,
had the ‘‘normal’’ Hsp70, C-terminal peptide-binding domain,
and all three provided cytoprotection under conditions of hy-
poxia-ischemia. Similar results were obtained in vivo. The con-
clusion is that Hsp70 can contribute to cytoprotection by
mechanisms that do not involve assisting protein folding
and/or refolding or interaction with cochaperones requiring
the N-terminal domain of the chaperone.10. Use of heat-shock promoters to drive other useful genes
The promoters of some molecular chaperone genes, e.g.,
hsp70, are considered strong, and easily inducible by means
of stressors that, although capable of inducing stress genes,
are relatively harmless [30]. Likewise, promoters have been
constructed that are inducible by clinically relevant stressors,
such as ischemia–hypoxia, and this promoter may be used to
drive chaperone genes, or other genes with therapeutic applica-
tions [31]. These publications are just two examples of the
many available, in which various genetic engineering ap-
proaches have been developed and tested for increasing the
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of chaperone molecules. The hope is that increasing the con-
centration of chaperone molecules inside a cell will ‘‘invigo-
rate’’ it, and made it capable of a rapid antistress response
accompanied by an increase in chaperoning potency.11. Pharmacological induction of chaperone genes
Based on the premise that chaperones protect from some of
the deleterious eﬀects of stress, many attempts have been made
to induce endogenous chaperone genes by using mild stressors,
which by themselves are expected not to cause harmful side ef-
fects. For example, a moderate whole body temperature eleva-
tion, or a more intense heating of a small, well delimited,
portion of the body, have been tested in attempts to cause ben-
eﬁcial stress responses accompanied by an increase in chaper-
one levels. The same eﬀects have been obtained with
chemical compounds know to induce stress genes. This strat-
egy was applied, for instance, to treat spinal and bulbar mus-
cular atrophy (SBMA) [32]. This disease is hereditary,
recessive, X-linked, aﬀecting males and only rarely females.
The main clinical manifestations are progressive muscle weak-
ness and atrophy, beginning in adulthood. Cramping, diﬃculty
in walking and in swallowing, speech abnormalities, muscle
twitching, and infertility, are common. A central molecular de-
fect resides in the androgen receptor (AR) protein, which due
to a mutation in its parent gene has an excess of glutamine res-
idues: the mutated gene carries an abnormal number of copies
the codon CAG (encoding glutamine). The polyglutamine ex-
panded AR is involved in pathogenesis via its accumulation in
the nucleus and interference with the normal process of tran-
scription of many genes. In a cell model of SBMA it was ob-
served that administration of geranylgeranylacetone (GGA)
reduced intranuclear accumulation of the defective AR and
the accompanying pathology. This eﬀect was attributed to
the fact that GGA increased the levels of Hsp70, Hsp90, and
Hsp105. Oral administration of GGA to transgenic mice with
a similar disease, also increased the levels of the Hsps in the
central nervous system and improved the clinical picture.
Similar results have been obtained with arimoclomol, also a
known hsp gene inducer, in an animal model of amyotrophic
lateral sclerosis (ALS) [33]. The protein superoxide dismu-
tase-1 (SOD1) is defective due to mutation of its gene in about
20% of familial ALS (FALS). In these cases, deposition of
defective SOD1 in cells has a toxic eﬀect. So the idea was to
interfere with the precipitation of the mutated protein by acti-
vating the hsp genes, using arimoclomol, and thus increase the
chaperoning capacity of the cell.12. Novel approaches to inducing chaperone genes could be
derived from new ﬁndings
It is known that motor neurons have a comparatively high
threshold for induction of hsp genes. Motor neurons do not re-
spond to stress as easily as other cell types, a characteristic
attributed to a low capacity to activate HSF-1, which must be-
come hyperphosphorylated if it will activate hsp genes. In a re-
cent work, it was demonstrated that the low response to stress
typical of motor neurons is not due to impaired phosphoryla-
tion of HSF-1 by kinases such as PKC, GSK3beta, ERK1, andCaMKIIalpha, which are known to activate this factor in
other cell types [34]. It was also shown that CaMKIV, a con-
stitutively active kinase, induced a strong Hsp70 response,
and transcription of a reporter gene driven by the human
inducible hsp70-gene promoter in unstressed motor neurons,
but not in embryonic ﬁbroblasts. These results direct attention
to novel mechanisms of chaperone-gene activation. Newly de-
scribed mechanisms of gene activation might oﬀer convenient
targets for research aimed at improving the stress response
by increasing chaperone levels when these molecules are re-
quired in greater quantities, for example, during stress.13. Chaperones used as vehicle for delivering therapeutic agents
and other compounds
Eﬀorts are being directed toward the development of vehi-
cles of large capacity (capable of carrying more than one com-
pound) but of small size (e.g., 5–100 nm; nanotechnology). In
addition, these vehicles must have the capacity of recognizing
speciﬁc targets (e.g., neurons of a certain type), namely the
vehicles must be endowed with cellular tropism.
Various chaperones form multimers to exercise their func-
tions, such as GroEL/S in bacteria and bacterial-related cell
organelles, and CCT in eukaryotes and archaea (reviewed in
[35]). Both, GroEL/S and CCT are formed by two superposed
rings made of 7 or 8 subunits, respectively. Thus, the entire
structure is barrel shaped with a central cavity opened at both
ends. This overall arrangement provides various surfaces
(chemical platforms) with potential for attaching useful com-
pounds for transportation: the outer surface, the inner surface
delimiting the central cavity, and exposed surfaces at the sub-
unit–subunit interfaces. While the GroEL/S and CCT struc-
tures are relatively big (in the range of 140–150 · 160–180 A˚
on the outside with an inner cavity in the range 80 · 85 A˚)
and this may limit their application as vehicles, other chaper-
ones form smaller structures. For instance, sHsp associate into
multimers, some quite large but still smaller than GroEL/S and
CCT, with the overall shape of sphere with a central cavity.
Furthermore, sHsp form a range of multimers made of two
or more subunits, thus one can choose which one to use. For
example, it was recently reported the use of a vehicle (120 ang-
stroms, i.e., 12 nm, in diameter) made of 24 sHsp subunits
from the archaeon Methanococcus jannaschii to deliver a ﬂuo-
rescent compound to melanoma cells, and thus allow speciﬁc
imaging of these cells [36]. The advantages of these biological
cages of small dimensions, nanocages, are many: the number
of subunits (namely size) can be controlled, the subunits can
be genetically or chemically modiﬁed to endow them with de-
sired properties, and the cages can be used to transport to spe-
ciﬁc places therapeutic agents, and labels for cell imaging via
ﬂuorescence or magnetic resonance.14. Conclusions and perspectives
There is ample evidence supporting the notion that molecu-
lar chaperones participate in the pathogenesis of disease [1,5]
and in the mechanisms of ageing [2,37]. Likewise, it has be-
come clear that chaperones oﬀer a promising alternative for
the prevention and treatment of a number of pathological con-
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also others, such as cancer, in which the pathogenetic mecha-
nism does not necessary include protein misfolding [8,9]. In
cancer for example, chaperones can be used as immunomodu-
lators to improve the immune response against tumors or as
carriers of poorly immunogenic tumor peptides, which by vir-
tue of being associated with the chaperone molecule elicit a
strong antitumor response.
Thus, the near future is promising in terms of new chaperon-
opathies discovered, advances in the understanding of those al-
ready identiﬁed, and expansion of chaperonotherapy at both,
the experimental and clinical levels. In this regard, novel and
very promising avenues for exploration are suggested by ﬁnd-
ings indicating that some chaperones are increased in certain
types of cancer cells and can enhance tumorigenesis [38–43].
For example, mRNAs from the molecular-chaperone genes
of the 70 kDa family, HSPA8 (protein named Hsc70, or
Hsp73), HSP1A (protein Hsp72, or Hsp70, or Hsp70-1a),
and HSP1B (protein Hsp72, or Hsp70, or Hsp70-1b) were
found increased in various degrees in all or the majority of
six tumorigenic and three immortalized but non-tumorigenic
cell lines tested [38]. The data indicated that the genes were
upregulated in the tumor cell lines. Furthermore, it was dem-
onstrated that tumor cells require Hsps for growth. By knock-
ing down hsp70 genes it was established that the growth of
tumorigenic cells depended on the presence of Hsp70 and
Hsp70-2 (from the gene HSPA2), and all cells, tumorigenic
or not, depended on the presence of Hsc70. In parallel, it
was found that Hsp70-2 was elevated in one third of all human
breast cancer biopsies examined. Similarly, expression of
Hsp60 was found increased during uterine and colorectal car-
cinogenesis [39–41], and expression of Hsp10 was also elevated
[41,42]. The mechanisms by which Hsps enhance tumor growth
are probably varied depending on the tumor type and the Hsp
involved but have not yet been elucidated. In this regard, the
impact on the cell cycle and the antiapoptic eﬀect that some
Hsps have may carry pathogenic consequences [38,43]. What-
ever the mechanism, it is obvious that normal chaperones can
play a role in pathogenesis, particularly when they are in-
creased as in the speciﬁc instances mentioned above. These
would represent examples of quantitative, dysregulatory chap-
eronopathies in which the chaperone genes are overexpressed
[4,5]. Pertinent treatment should include measures to decrease
expression of the chaperone-genes whose protein products are
speciﬁcally responsible for pathogenesis and to deplete cells or
the organism of these proteins.
In summary, with regard to cancer, chaperones may be used
as anti-cancer agents to help in the induction of anti-tumor
immunity, or conversely, as targets for anti-chaperone agents
when chaperones contribute to disease. Along similar lines
and also with a very promising future are the ﬁelds of applied
chaperonology–chaperonotherapy and anti-chaperone agents
in industrial settings, such as those aiming at improving plant
and animal health and growth. An example of industry that
can beneﬁt from chaperonotherapy is that focused on the cul-
tivation of water produce (e.g., ﬁsh and shellﬁsh), in which it
has become necessary to preserve and improve the chaperon-
ing systems so the organisms can deal better with stressors
(e.g., pollutants) in natural habitats and in man-made environ-
ments such as aquaculture installations. At the same time, it
would be convenient to disarm the chaperoning systems of
the parasites that plague the useful species using anti-chaper-one agents. Thus, the development of anti-chaperone agents
for downregulating chaperone genes, or for blocking chaper-
one functions can be predicted to become a very active ﬁeld
in the next few years.
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